

## عنوان مقاله:

Experimental And Molecular Docking Study Of Novel Heterocyclic Compounds Against FLT3 Receptor TyrosineKinase

## محل انتشار:

دومین سمپوزیوم بین المللی سرطان نسترن (سال: 1395)

تعداد صفحات اصل مقاله: 1

## نویسندگان:

Mohammad Hossein Tanipour - *Department Of Medical Biochemistry, School Of Medicine, Mashhad University Of Medical Sciences, Mashhad, Iran*

Mostafa Akhlaghi Bagherjeri - *Department Of Medical Biochemistry, School Of Medicine, Mashhad University Of Medical Sciences, Mashhad, Iran*

Hassan Ostadi - *Department Of Medical Biochemistry, School Of Medicine, Mashhad University Of Medical Sciences, Mashhad, Iran*

Mohammad Saadatmandzadeh - *Faculty Of Sciences, Department Of Chemistry, Ferdowsi University Of Mashhad, Mashhad, Iran*

## خلاصه مقاله:

Cancers, including Leukemia, are major causes of human mortality. Leukemia is the most common cancer diagnosis in children who are younger than 15 years. Acute Myeloid Leukemia (AML) have been recognized as a prevalent type of leukemia by 25-30% of all. Internal tandem duplications (ITD) and point mutations in the tyrosine kinase domain (TKD) of the FLT3 receptor (FMS-Like Tyrosine kinase) are the most common genetic alterations in AML. Small Molecules Inhibitors (SIMs) of the mutated kinases are considered as one of the most promising molecular strategies to combat with such genetic defects. A set of 8 novel heterocyclic compounds composed of a common core (7,7-dimethyl-7,8-dihydro-6H-tetrazolo[1,5-b][4,1,2]benzothiadiazin-6-one) structure and different substituents used in this study. Two murine cell lines of FD-FLT3-WT and FD-FLT3-ITD dependent to human FLT3 receptor were used for doing cellular examinations. Cytotoxicity evaluation was performed using Resazurin reagent for both cell lines in the presence of various growth factors (FLT3 ligand and GM-CSF) for the FD-FLT3-WT line to achieve IC<sub>50</sub>. The interactions of the inhibitor compounds and the homology models FLT3 were evaluated by molecular docking method using GOLD and Accelrys Discovery Studio software. The D8 compound with the amino substituent could result in the IC<sub>50</sub> values of 14.28 and 0.93 μM, respectively, in two cell lines of FD-FLT3-ITD and FD-FLT3-WT. However, two D1 and D2 compounds were effective against the FD-FLT3-ITD line, but not on the FD-FLT3-WT cell line. Also, the docking results indicate these compounds were docked with more favorable energy at the active forms of the receptor (homology models built based on 1PKG and 2GQG). In both experimental and in silico studies, compounds D1, D2 and D8 were considered as the best compounds of this category due to their specific activity and potent receptor-ligand interactions.

## کلمات کلیدی:

